Cellosaurus OVTOKO (CVCL_3117)

Cell line name OVTOKO
Accession CVCL_3117
Resource Identification Initiative To cite this cell line use: OVTOKO (RRID:CVCL_3117)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Ovarian clear cell adenocarcinoma (NCIt: C40078)
Derived from metastatic site: Spleen.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO12
D13S3178,12
D16S53911,12
D18S5119
D21S1129,31
D3S135815
D5S81811,12
D7S8209,10
D8S117910,14
FGA21,23
Penta D9,10
Penta E14
TH016,9.3
TPOX8,12
vWA14,17
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=9328139; DOI=10.1038/bjc.1997.471
Yanagibashi T., Gorai I., Nakazawa T., Miyagi E., Hirahara F., Kitamura H., Minaguchi H.
Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20.
Br. J. Cancer 76:829-835(1997)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567
Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I.
Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Cancer Res. 67:7095-7105(2007)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23430509; DOI=10.1007/s13577-013-0062-y
Itamochi H., Kato M., Nishimura M., Oumi N., Oishi T., Shimada M., Sato S., Naniwa J., Sato S., Nonaka M., Kudoh A., Terakawa N., Kigawa J., Harada T.
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
Hum. Cell 26:121-127(2013)

PubMed=23839242; DOI=10.1038/ncomms3126
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126-2126(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections JCRB; JCRB1048
JCRB; NIHS0301 - Discontinued
JCRB; NIHS0343 - Discontinued
Cell line databases/resources CCLE; OVTOKO_OVARY
CGH-DB; 331-2
Cosmic-CLP; 1298365
GDSC; 1298365
LINCS_LDP; LCL-1528
Ontologies BTO; BTO:0003499
EFO; EFO_0006728
Biological sample resources BioSample; SAMN03472861
Gene expression databases GEO; GSM459732
GEO; GSM659399
GEO; GSM827253
GEO; GSM887490
GEO; GSM888572
GEO; GSM1176282
GEO; GSM1670325
Polymorphism and mutation databases Cosmic; 1223318
Cosmic; 1328067
Cosmic; 1434895
Cosmic; 1708379
Cosmic; 1889263
Cosmic; 2074248